Ken Griffin Vertex Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 209,500 shares of VRTX stock, worth $97.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

209,500

Previous 135,400 54.73%

Holding current value

$97.9 Million

Previous $63.5 Million 53.53%

% of portfolio

0.02%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $25 Million - $27.5 Million	-54,363 Reduced 51.97%	50,232 $23.4 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $8.89 Million - $11 Million	22,622 Added 27.6%	104,595 $49 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $99.8 Million - $109 Million	-244,707 Reduced 74.91%	81,973 $34.3 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $103 Million - $123 Million	298,936 Added 1077.48%	326,680 $133 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $9.34 Million - $10 Million	27,631 Added 24452.21%	27,744 $9.65 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $26.3 Million - $29.5 Million	-83,693 Reduced 99.87%	113 $39,000
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $33.9 Million - $38.7 Million	-119,805 Reduced 58.84%	83,806 $26.4 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $54.3 Million - $61 Million	189,846 Added 1379.19%	203,611 $58.8 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $3.77 Million - $4.21 Million	13,765 New	13,765 $3.99 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $46.5 Million - $54.8 Million	-209,986 Reduced 83.13%	42,605 $11.1 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $28.6 Million - $36.1 Million	-161,538 Reduced 39.01%	252,591 $55.5 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $4.45 Million - $4.98 Million	24,539 Added 6.3%	414,129 $75.1 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $249 Million - $294 Million	-1,329,590 Reduced 77.34%	389,590 $78.6 Million
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $49.9 Million - $58.1 Million	240,821 Added 16.29%	1,719,180 $369 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $117 Million - $156 Million	566,347 Added 62.1%	1,478,359 $349 Million
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $119 Million - $141 Million	465,056 Added 104.05%	912,012 $248 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $117 Million - $145 Million	-583,879 Reduced 56.64%	446,956 $106 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $52.7 Million - $70.8 Million	316,096 Added 44.23%	1,030,835 $226 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $95.4 Million - $107 Million	573,869 Added 407.37%	714,739 $121 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $543,048 - $628,030	3,299 Added 2.4%	140,870 $25.8 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $122 Million - $145 Million	-745,952 Reduced 84.43%	137,571 $0
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $8.31 Million - $10.5 Million	54,690 Added 6.6%	883,523 $146 Million
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $117 Million - $134 Million	-696,560 Reduced 45.66%	828,833 $0
Q2 2018 Aug 10, 2018	BUY	$145.72 - $169.96 $109 Million - $127 Million	749,719 Added 96.65%	1,525,393 $0
Q1 2018 May 11, 2018	SELL	$151.6 - $177.13 $142 Million - $166 Million	-938,586 Reduced 54.75%	775,674 $126 Million
Q4 2017 Feb 09, 2018	BUY	$137.28 - $155.55 $50.3 Million - $57 Million	366,651 Added 27.21%	1,714,260 $257 Million
Q3 2017 Nov 09, 2017	BUY	$148.13 - $162.24 $200 Million - $219 Million	1,347,609	1,347,609 $205 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account